FDA's Vancocin Rule-Bend: Generic Floodgate's Future?

As the last line of defense against killer bugs, ViroPharma Inc.'s generics-threatened Vancocin (vancomycin) is "particularly ill-suited to being the test case" for an FDA plan to change the standards for bioequivalence testing of nonsystemically absorbed drugs. So wrote Michel de Rosen, CEO of ViroPharma, in a letter to the agency. (BioWorld Financial Watch)